Cannabinoid Treatments for Rare and Less-Common Diseases: What We Know So Far
Cannabinoids show promise for rare conditions like refractory epilepsies, dystonia, Tourette syndrome, and epidermolysis bullosa, but advanced drug delivery systems are needed to overcome bioavailability challenges.
Quick Facts
What This Study Found
Recent evidence supports cannabinoid use in rare epilepsies beyond Dravet/Lennox-Gastaut, movement disorders, and rare skin diseases, while Fragile X syndrome trials revealed methodological challenges instructive for future research.
Key Numbers
Review covered evidence from 2020-2025 across multiple rare conditions including refractory epilepsies, dystonia, Tourette syndrome, epidermolysis bullosa, and Crohn's disease.
How They Did This
Critical review synthesizing 2020-2025 evidence from PubMed and Scopus on cannabinoid therapies in less-common disorders, including formulation and delivery optimization strategies.
Why This Research Matters
Patients with rare diseases often have few treatment options — cannabinoids could fill therapeutic gaps, but only if formulation challenges like poor bioavailability are solved.
The Bigger Picture
The intersection of cannabinoid medicine and orphan diseases represents a frontier where unmet medical need is high and novel delivery systems could make the difference between theoretical promise and clinical reality.
What This Study Doesn't Tell Us
Most evidence is preclinical or from small clinical studies; the review covers heterogeneous conditions making direct comparisons difficult.
Questions This Raises
- ?Which rare disease applications will advance to pivotal trials first?
- ?Can nanocarrier systems and transdermal gels solve cannabinoid bioavailability problems?
Trust & Context
- Key Stat:
- Evidence Grade:
- Comprehensive review of recent literature, but underlying evidence base is largely preclinical with small clinical studies for most conditions reviewed.
- Study Age:
- Published in 2026, covering the most recent 5 years of evidence (2020-2025) in this rapidly evolving field.
- Original Title:
- Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies.
- Published In:
- Diseases (Basel, Switzerland), 14(2) (2026)
- Authors:
- Afonso, Silvia, Gonçalves, Joana, Brinca, Ana T, Rosendo, Luana M, Rosado, Tiago, Duarte, Ana Paula, Gallardo, Eugenia
- Database ID:
- RTHC-08065
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
Can cannabinoids help with rare diseases?
There's emerging evidence for conditions like rare epilepsies, dystonia, Tourette syndrome, and epidermolysis bullosa, but most evidence is preliminary and more clinical trials are needed.
Why is drug delivery a challenge for cannabinoid medicines?
Cannabinoids have poor bioavailability when taken orally, meaning much of the dose is lost before reaching its target. New delivery systems like nanocarriers and transdermal gels aim to solve this.
Read More on RethinkTHC
- THC-purity-potency-label-meaning
- dab-concentrate-addiction-withdrawal
- delta-8-addiction-withdrawal
- edible-addiction-withdrawal-different
- edibles-psychosis-emergency-room
- healthiest-way-to-consume-cannabis
- how-cannabis-products-made-concentrates-edibles
- laced-weed-fentanyl-contaminated-vape
- legal-weed-vs-street-weed-quality-safety
- quitting-dabs-withdrawal
- quitting-edibles-withdrawal
- sativa-vs-indica-difference-myth
- weed-potency-withdrawal
- sublingual-vs-oral-vs-inhaled-thc-absorption
- cannabis-and-tourettes-syndrome-tic-reduction
Cite This Study
https://rethinkthc.com/research/RTHC-08065APA
Afonso, Silvia; Gonçalves, Joana; Brinca, Ana T; Rosendo, Luana M; Rosado, Tiago; Duarte, Ana Paula; Gallardo, Eugenia. (2026). Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies.. Diseases (Basel, Switzerland), 14(2). https://doi.org/10.3390/diseases14020083
MLA
Afonso, Silvia, et al. "Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies.." Diseases (Basel, 2026. https://doi.org/10.3390/diseases14020083
RethinkTHC
RethinkTHC Research Database. "Cannabinoid Therapies in Less-Common Disorders: Clinical Evi..." RTHC-08065. Retrieved from https://rethinkthc.com/research/afonso-2026-cannabinoid-therapies-in-lesscommon
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.